Onconova Therapeutics
Stock Forecast, Prediction & Price Target
Onconova Therapeutics Financial Estimates
Onconova Therapeutics Revenue Estimates
Onconova Therapeutics EBITDA Estimates
Onconova Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $226K N/A | $226K 0% | $226K 0% | Avg: $300K Low: $289.65K High: $310.34K avg. 32.74% | Avg: $300K Low: $289.65K High: $310.34K avg. 0% | Avg: $300K Low: $289.65K High: $310.34K avg. 0% | Avg: $400K Low: $386.20K High: $413.79K avg. 33.33% |
Net Income
% change YoY
| $-15.82M N/A | $-18.30M -15.62% | $-18.94M -3.53% | Avg: $-28.4M Low: $-18.20M High: $-16.63M avg. -49.88% | Avg: $-33M Low: $-17.76M High: $-16.23M avg. -16.19% | Avg: $-19.93M Low: $-20.83M High: $-19.04M avg. 39.57% | Avg: $-24.34M Low: $-25.43M High: $-23.25M avg. -22.10% |
EBITDA
% change YoY
| $-16.81M N/A | $-19.62M -16.70% | $-20.28M -3.33% | Avg: $-300K Low: $-310.34K High: $-289.65K avg. 98.52% | Avg: $-300K Low: $-310.34K High: $-289.65K avg. 0% | Avg: $-300K Low: $-310.34K High: $-289.65K avg. 0% | Avg: $-400K Low: $-413.79K High: $-386.20K avg. -33.33% |
EPS
% change YoY
| -$0.94 N/A | -$0.88 6.38% | -$0.9 -2.27% | Avg: -$0.83 Low: -$0.87 High: -$0.79 avg. 7.77% | Avg: -$0.81 Low: -$0.85 High: -$0.77 avg. 2.40% | Avg: -$0.95 Low: -$0.99 High: -$0.91 avg. -17.28% | Avg: -$1.16 Low: -$1.21 High: -$1.11 avg. -22.10% |
Operating Expenses
% change YoY
| $16.72M N/A | $19.85M 18.72% | $20.52M 3.37% | Avg: $9.55M Low: $9.22M High: $9.88M avg. -53.46% | Avg: $9.55M Low: $9.22M High: $9.88M avg. 0% | Avg: $9.55M Low: $9.22M High: $9.88M avg. 0% | Avg: $12.73M Low: $12.29M High: $13.17M avg. 33.33% |
FAQ
What is Onconova Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -12.15% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -18.20M, average is -28.4M and high is -16.63M.
What is Onconova Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 16.51% in 2025-2028.
We have gathered data from 1 analysts. Their low revenue estimate is $289.65K, average is $300K and high is $310.34K.
What is Onconova Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -7.30% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$0.87, average is -$0.83 and high is $-0.79.
What is the best performing analyst?
In the last twelve months analysts have been covering Onconova Therapeutics stock. The most successful analyst is Ahu Demir.